These cannabis stocks could be worth it

Frankfurt After their first boom, cannabis stocks are now also picking up speed in Germany. The reason: The Ampelkoalition wants to introduce a “controlled distribution of cannabis to adults for consumption purposes in licensed shops” – so it says in the coalition agreement. Since the beginning of the year, investors have been able to trade shares in Synbiotic (ISIN DE000A3E5A59), the first cannabis company from Germany, on the stock exchange.

After a massive price upswing, the company has had a stock market valuation of almost 150 million euros since mid-November, but has not yet made a profit. Synbiotic sees itself as a “platform”. It invests itself in companies that are active in different sections of the value chain of medical cannabis products.

The share can only be found three times in the Bloomberg data service – each at smaller financial institutions. But all recommendations are “buy”. To the delight of Synbiotic CEO Lars Müller: “The new government in Germany is now giving us additional tailwind.”